AI APPROACH
Rank hypotheses by mechanism and selectivity-the laboratory confirms, rejects, or redirects each one.
Why combinations
Single agents fail. Combinations win.
Most cancers are not single-pathway diseases. The AI is designed for the combinatorial search space - not for one-target-at-a-time medicinal chemistry.
The model decomposes a tumor's omics signature into pathway dependencies, then searches over combinations of FDA-approved interventions that hit them simultaneously.
Multi-pathway combinations designed to target central cancer-driving mechanisms across tumor types.
Data foundation
Trained on a substrate the literature already trusts.
1,000+
Cancer cell lines analyzed for response signatures
17
Rediscovered standards of care during in-silico validation across 17 cancers.
6
combinations showed broad efficacy across 10+ cancers ex-vivo
The AI is only as honest as the assay it is held to.
- Validation principle